Your Guide to Buying Funeral Equipment in South Carolina
Latest Advances in Ambulance Stretchers: A Buyer’s Guide
5 Key Features to Consider When Purchasing Mortuary Cots
Top Features to Look for in the Best Hydraulic Embalming Table from Mobimedical
Portable vs. Fixed Embalming Tables: Which is Right for Your Funeral Home?
Cardiac Insight has stated that they have currently raised around $4.5 million in their new round of C-1 funding. They are hoping to acquire at least $10 million in this new round of funding to help back their cutting-edge product, the Cardea Solo 7-day ECG sensor.
The funding from this new round will go to support marketing, distribution and sales of the company’s state-of-the-art wearable device. Their one of a kind device was created to supply cardiac data to both the patient and their doctors, in order to help diagnose an array of different arrhythmias, such as atrial fibrillation.
In a prepared statement the CEO and co-founder of Cardiac Insight stated, “Cardiac Insight has swiftly gained the attention of the cardiology community for our game-changing products and revolutionary approach to cardiac care. Our new funding and leadership additions will continue to propel the company forward and highlight our distinct value proposition to cardiologists, healthcare institutions and patients.”
The company is based in Kirkland, Washington and has done its homework. Along with raising the much needed funding to propel their project, it has already created its own scientific advisory board. And, this board will be led by none other than the former Heart Rhythm Society president Dr. Robert Hauser. Another great addition to the Cardiac Insight team is Clifford Stocks, the CEO of OncoResponse,. Mr. Stocks will have a seat on the company’s board of directors. Dr. Hauser and Mr. Stocks are a great addition to this team and will only help to improve the project.
In a press release Stocks stated, “Cardiac Insight brings exclusive technology capabilities that will help save lives and empower healthcare providers with control over data and the patient experience, as well as increased efficiencies for the diagnosis and treatment of cardiac care. I am honored to serve with a group of healthcare executives who bring impressive track records in building new med-tech platforms.”
In early July, Cardiac Insight publicly announced the launch of their new device the Cardea Solo, and we can not wait to see the effect this product will have on the medical industry and what the future may hold for this company.
SEPTEMBER 7, 2017